CO6382184A2 - Proteinas fijadoras de receptores de interleukinas-21 - Google Patents
Proteinas fijadoras de receptores de interleukinas-21Info
- Publication number
- CO6382184A2 CO6382184A2 CO10160884A CO10160884A CO6382184A2 CO 6382184 A2 CO6382184 A2 CO 6382184A2 CO 10160884 A CO10160884 A CO 10160884A CO 10160884 A CO10160884 A CO 10160884A CO 6382184 A2 CO6382184 A2 CO 6382184A2
- Authority
- CO
- Colombia
- Prior art keywords
- fixing
- antigen
- fragment
- protein
- interleukinas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
1.- Una proteína fijadora aislada o fragmento fijador de antígenos de la misma que se fija a IL-21 R, en donde la proteína fijadora o fragmento fijador de antígenos de la misma comprende al menos una secuencia aminoácida que es al menos aproximadamente 95% idéntica a una secuencia aminoácida seleccionada del grupo que consta de SEQ LD NOs: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42,44,46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120,122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 165-168, 171-193, 213-229, 240, 242, 244, 246, y 248.2.- La proteína fijadora aislada o fragmento fijador de antígenos de la reivindicación 1, en donde la proteína fijadora o fragmento fijador de antígenos es un anticuerpo.3.- La proteína fijadora aislada o fragmento fijador de antígenos de la reivindicación 1, en donde la proteína fijadora o fragmento fijador de antígenos es un scFv.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5550008P | 2008-05-23 | 2008-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6382184A2 true CO6382184A2 (es) | 2012-02-15 |
Family
ID=41112652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10160884A CO6382184A2 (es) | 2008-05-23 | 2010-12-22 | Proteinas fijadoras de receptores de interleukinas-21 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8163884B2 (es) |
| EP (1) | EP2297199A1 (es) |
| JP (1) | JP2011523849A (es) |
| KR (1) | KR20110040773A (es) |
| CN (1) | CN102105491A (es) |
| AR (1) | AR071885A1 (es) |
| AU (1) | AU2009248809A1 (es) |
| CA (1) | CA2724915A1 (es) |
| CL (1) | CL2009001284A1 (es) |
| CO (1) | CO6382184A2 (es) |
| IL (1) | IL209328A0 (es) |
| MX (1) | MX2010012811A (es) |
| MY (1) | MY149448A (es) |
| NZ (1) | NZ589330A (es) |
| PE (1) | PE20100141A1 (es) |
| RU (1) | RU2010152690A (es) |
| SA (1) | SA109300315B1 (es) |
| TW (1) | TW201000129A (es) |
| WO (1) | WO2009143523A1 (es) |
| ZA (1) | ZA201008335B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| EP2518084B1 (en) * | 2009-12-25 | 2016-11-30 | Sekisui Medical Co., Ltd. | Method for measuring human insulin and measurement reagent |
| US8846603B2 (en) * | 2010-03-12 | 2014-09-30 | Synageva Biopharma Corp. | NPP1 fusion proteins |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US6576744B1 (en) | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| EP1165791B1 (en) | 1999-03-09 | 2007-10-31 | ZymoGenetics, Inc. | Human cytokine as ligand of the zalpha receptor and uses thereof |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| WO2000069880A1 (en) | 1999-05-18 | 2000-11-23 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
| ATE349522T1 (de) | 2000-04-05 | 2007-01-15 | Zymogenetics Inc | Löslicher zytokinrezeptor zalpha11 |
| PT1353953E (pt) | 2000-05-11 | 2007-02-28 | Genetics Inst Llc | Mu-1, membro da família dos receptores de citocina |
| EP1451322B1 (en) | 2001-11-05 | 2009-09-30 | ZymoGenetics, Inc. | Il-21 antagonists |
| US20040016010A1 (en) | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| EP2289525A1 (en) | 2002-06-07 | 2011-03-02 | ZymoGenetics, Inc. | Use of IL-21 for expanding lymphoid cells and for anticancer adoptive immunotherapy |
| EP1553982A4 (en) | 2002-07-15 | 2008-03-26 | Wyeth Corp | METHOD AND COMPOSITIONS FOR MODULATING THE DEVELOPMENT AND FUNCTION OF T-HELPER CELLS (T sb H / sb) |
| EP2184298A1 (en) * | 2003-03-14 | 2010-05-12 | Wyeth a Corporation of the State of Delaware | Antibodies against human IL-21 receptor and uses therefor |
| AU2004224277A1 (en) | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| AU2005244942A1 (en) | 2004-05-19 | 2005-12-01 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| US20060039902A1 (en) | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| CN101052419A (zh) * | 2004-08-05 | 2007-10-10 | 惠氏公司 | 拮抗白介素－21受体活性 |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2008081198A1 (en) | 2007-01-05 | 2008-07-10 | Imperial Innovations Ltd | Blood assays for predicting inflammatory responses |
-
2009
- 2009-05-22 AR ARP090101847A patent/AR071885A1/es not_active Application Discontinuation
- 2009-05-22 PE PE2009000719A patent/PE20100141A1/es not_active Application Discontinuation
- 2009-05-23 SA SA109300315A patent/SA109300315B1/ar unknown
- 2009-05-25 CL CL2009001284A patent/CL2009001284A1/es unknown
- 2009-05-25 TW TW098117296A patent/TW201000129A/zh unknown
- 2009-05-26 CA CA2724915A patent/CA2724915A1/en not_active Abandoned
- 2009-05-26 WO PCT/US2009/045182 patent/WO2009143523A1/en active Application Filing
- 2009-05-26 RU RU2010152690/10A patent/RU2010152690A/ru not_active Application Discontinuation
- 2009-05-26 JP JP2011510744A patent/JP2011523849A/ja active Pending
- 2009-05-26 KR KR1020107028877A patent/KR20110040773A/ko not_active Application Discontinuation
- 2009-05-26 MY MYPI2010005509A patent/MY149448A/en unknown
- 2009-05-26 MX MX2010012811A patent/MX2010012811A/es active IP Right Grant
- 2009-05-26 US US12/472,209 patent/US8163884B2/en not_active Expired - Fee Related
- 2009-05-26 NZ NZ589330A patent/NZ589330A/xx not_active IP Right Cessation
- 2009-05-26 EP EP09751751A patent/EP2297199A1/en not_active Withdrawn
- 2009-05-26 AU AU2009248809A patent/AU2009248809A1/en not_active Abandoned
- 2009-05-26 CN CN200980128968XA patent/CN102105491A/zh active Pending
-
2010
- 2010-11-15 IL IL209328A patent/IL209328A0/en unknown
- 2010-11-19 ZA ZA2010/08335A patent/ZA201008335B/en unknown
- 2010-12-22 CO CO10160884A patent/CO6382184A2/es not_active Application Discontinuation
-
2012
- 2012-04-23 US US13/453,090 patent/US20120264919A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8163884B2 (en) | 2012-04-24 |
| TW201000129A (en) | 2010-01-01 |
| PE20100141A1 (es) | 2010-02-22 |
| JP2011523849A (ja) | 2011-08-25 |
| KR20110040773A (ko) | 2011-04-20 |
| US20090298167A1 (en) | 2009-12-03 |
| MY149448A (en) | 2013-08-30 |
| AR071885A1 (es) | 2010-07-21 |
| RU2010152690A (ru) | 2012-06-27 |
| US20120264919A1 (en) | 2012-10-18 |
| ZA201008335B (en) | 2014-04-30 |
| WO2009143523A1 (en) | 2009-11-26 |
| IL209328A0 (en) | 2011-01-31 |
| CN102105491A (zh) | 2011-06-22 |
| CA2724915A1 (en) | 2009-11-26 |
| NZ589330A (en) | 2012-12-21 |
| SA109300315B1 (ar) | 2012-08-28 |
| EP2297199A1 (en) | 2011-03-23 |
| CL2009001284A1 (es) | 2009-11-27 |
| MX2010012811A (es) | 2011-05-19 |
| AU2009248809A1 (en) | 2009-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| CO6382184A2 (es) | Proteinas fijadoras de receptores de interleukinas-21 | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| CO6280541A2 (es) | Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40 | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| CR20110400A (es) | Proteinas de enlace al receptor cgrp humano | |
| CL2012003245A1 (es) | Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp. | |
| PE20150222A1 (es) | Anticuerpos multiespecificos | |
| MX2016011934A (es) | Inmunoglobulina hibrida conteniendo un enlace no-peptidilico. | |
| GT200600186A (es) | Agentes de unión | |
| CY1114658T1 (el) | Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| UA111818C2 (uk) | Антитіло проти csf-1r | |
| EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| CO5720212A1 (es) | Composicion de anticuerpo her2 | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
| EA201100868A1 (ru) | Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| EA201291065A1 (ru) | Антитела против vla-4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |